- Home
- CAVA vs EXAS Comparison
CAVA vs EXAS Comparison
Compare CAVA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- EXAS
- Stock Information
- Founded
- CAVA 2006
- EXAS 1995
- Country
- CAVA United States
- EXAS United States
- Employees
- CAVA N/A
- EXAS N/A
- Industry
- CAVA Restaurants
- EXAS Medical Specialities
- Sector
- CAVA Consumer Discretionary
- EXAS Health Care
- Exchange
- CAVA Nasdaq
- EXAS Nasdaq
- Market Cap
- CAVA 8.6B
- EXAS 10.7B
- IPO Year
- CAVA 2023
- EXAS N/A
- Fundamental
- Price
- CAVA $82.79
- EXAS $53.86
- Analyst Decision
- CAVA Buy
- EXAS Strong Buy
- Analyst Count
- CAVA 15
- EXAS 20
- Target Price
- CAVA $115.87
- EXAS $70.16
- AVG Volume (30 Days)
- CAVA 4.2M
- EXAS 2.8M
- Earning Date
- CAVA 08-21-2025
- EXAS 07-30-2025
- Dividend Yield
- CAVA N/A
- EXAS N/A
- EPS Growth
- CAVA 274.67
- EXAS N/A
- EPS
- CAVA 1.20
- EXAS N/A
- Revenue
- CAVA $1,036,533,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- CAVA $26.28
- EXAS $14.58
- Revenue Next Year
- CAVA $21.53
- EXAS $12.75
- P/E Ratio
- CAVA $68.98
- EXAS N/A
- Revenue Growth
- CAVA 32.11
- EXAS 11.57
- 52 Week Low
- CAVA $70.00
- EXAS $39.97
- 52 Week High
- CAVA $172.43
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CAVA 56.44
- EXAS 51.90
- Support Level
- CAVA $72.36
- EXAS $52.60
- Resistance Level
- CAVA $85.24
- EXAS $55.09
- Average True Range (ATR)
- CAVA 3.55
- EXAS 2.15
- MACD
- CAVA 1.40
- EXAS -0.02
- Stochastic Oscillator
- CAVA 74.70
- EXAS 51.57
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.